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Multiple putative hepatocellular carcinoma (HCC) driver mutations have been identified using next-generation sequencing, but the majority have not been confirmed in *in vivo* settings or in combination with each other. Wang *et al*. describe a high-throughput solution by transducing transgenic mice containing a Cre-dependent Cas9 with hepatocyte-specific adeno-associated virus vectors that encode for Cre recombinase, EGFP and a sgRNA from a library, targeting HCC candidate genes (49 genes drawn from online databases). Indels at target loci were then confirmed and quantified using multiplexed molecular inversion probe sequencing.

Within 3 months of transduction, mice developed multifocal GFP-positive HCC, in which significant enrichment of *Trp 53*, *Setd2*, *Cic* and *Pik3R1* mutations were observed. Several pairs of mutations were significantly enriched, including *Cdkn2a* and *Pten*, *B2m* and *Kansl1*, and *Arid2* and *Cdkn2a*. This exciting novel HCC model has the potential to confirm thousands of gene candidates identified by sequencing projects.
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Hepatoma cell lines do not recapitulate many features of liver cancers, including histological morphology and subclonal heterogeneity. Nuciforo *et al*. describe a workflow to produce tumor organoids from primary tumor tissues (HCC and cholangiocarcinomas). The authors characterize histological, molecular and genomic features of the primary liver tumors, liver organoids and xenograft organoid tumors established in immunodeficient mice.

Tumors of multiple etiologies supported organoid establishment and culturing for up to 32 weeks. Coverage of different tumor genetic subtypes was observed. Histology and cancer markers expression of the primary tumor were both maintained in respective organoids and xenografts, suggesting these factors are independent of the liver microenvironment. Primary tumor subclonal mutations were observed at similar frequencies in the organoids, showing that a range of cells (and not a select few clones) establishes the organoids. This method opens up broad possibilities to observe more physiologically accurate processes in tumor biology.
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Given the genetic heterogeneity in HCCs, DNA mutations are difficult to use as biomarkers. Jiang *et al*. explore an alternate approach by characterizing DNA fragments in the circulation of HCC patients and healthy controls using PCR-free deep sequencing. The authors found that the size of circulating DNA fragments displays a nonrandom distribution and showed preferred sites of fragmentation. Interestingly, in HCC patients, both the fragment size distribution and the sites of preferred fragmentation of the circulating DNA significantly change. Using a training set of a liver cancer patient, the authors define a 'cancer-associated' set of preferred fragment ends and then differentiated (with an area under the curve value of 0.88) HCC patients (n = 90) from healthy, liver disease and liver cirrhosis controls (n = 32, 67, 36) by their circulating DNA fragments. This approach could present a novel way to detect HCC, despite its many genetic manifestations.
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